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In recent years, it is recognized that acquired immunity is controlled by regulatory T cell (Treg). Since fundamental
pathophysiological changes of allergy are mainly caused by hyperresponsiveness of immune system to allergens
that acquires after birth, Tregs likely play key roles in the pathogenesis of allergy, particularly during the sensitization
phase. However, accumulated information indicate that there are several distinctive subtypes of Tregs in man, and
each of them seems to play different role in controlling immune system, which complicates the involvement of
Tregs in allergy. The aim of the present study is to attempt to classify subtypes of Tregs and summarize their roles in
allergy. Tregs should include natural Tregs (nTreg) including inducible costimulator (ICOS)(+) Tregs, inducible/
adaptive Tregs (iTreg), interleukin (IL)-10-producing type 1 Tregs (Tr1 cells), CD8(+) Tregs and IL-17-producing Tregs.
These cells share some common features including expression of Foxp3 (except for Tr1 cells), and secretion of
inhibitory cytokine IL-10 and/or TGF-β. Furthermore, it is noticeable that Tregs likely contribute to allergic disorders
such as dermatitis and airway inflammation, and play a crucial role in the treatment of allergy through their actions
on suppression of effector T cells and inhibition of activation of mast cells and basophils. Modulation of functions of
Tregs may provide a novel strategy to prevent and treat allergic diseases.
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Allergic diseases are major diseases involving approxi-
mately 22% world population [1]. The diseases include
allergic rhinitis, allergic asthma, allergic dermatitis, allergic
conjunctitis, anaphylaxis, food or drug allergic reactions
etc. It has long been accepted that allergic inflammation is
the fundamental pathological changes of allergy, and type
I hypersensitivity of immune system is the basic mechan-
ism of allergic inflammation [2]. There are two phases in
the basic process of IgE mediated allergic inflammation,
the sensitization phase and effection phase.
It has long been recognized that lymphocytes guide
(if not dictate) the sensitization of allergy by directing dif-
ferentiation of uncommitted (naive) CD4 (+) T helper
(Th) cells towards Th1, Th2, Th17 and Treg pheno-
types. For example, the presence of IL-12 in the local* Correspondence: shoahenghe@hotmail.com
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unless otherwise stated.milieu skews towards Th1 [expression of T box expressed
in T cells (T-bet)], IL-4 towards Th2 (expression of
GATA-3), transforming growth factor (TGF)-β towards
Treg [expression of forkhead box P3 (Foxp3)] and IL-6
and TGF-β towards Th17 (expression of RORgammat) in
murine CD4(+) T cells. It has also been demonstrated
that the skewing of murine Th towards Th17 and Treg is
mutually exclusive, notably the presence of IL-6 may re-
sult in a shift from a regulatory phenotype towards a
Th17 [3]. It is clear that individuals with defective or sub-
optimal Foxp3 expression due to mutations in Foxp3
gene or in genes that promote Foxp3 expression such as
STAT5b are susceptible to allergic diseases [4]. Very re-
cently, it has been noticed that insufficient Treg and Th1
cells may be associated with the allergic inflammation
that may be attributed to the Th2 immune response in
patients suffering from allergic rhinitis who are sensitive
to olive pollen [5].
In recent years, Tregs have been emerging as key focus
in the sensitization phase of the pathogenesis of allergy.
It is recognized that acquired immunity is controlled by
Tregs that suppress responses of effector T cells. TregsLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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costimulator (ICOS)(+) Tregs [7], iTregs [4], Tr1 cells
[8], CD8(+) Tregs [9] and IL-17-producing Tregs [10].
These cells share some common features including ex-
pression of Foxp3 (except for Tr1 cells), and secretion of
inhibitory cytokine IL-10 and/or TGF-β (Table 1).
Subsets of Tregs
At least 5 subsets of Tregs are identified so far. They are
derived from naive T cells under different conditions,
and play a crucial role in controlling allergic diseases.
nTregs
The CD4(+)CD25(+)Foxp3(+) cells, which secret IL-10
and TGF-β, and represent one of the largest subsets of
Treg. In mice, the cytokines associated with the Treg
subset include both soluble and cell membrane-bound
TGF-β and IL-10. Both contact-dependent mechanisms
involving membrane-bound TGF-β to block T cell prolif-
eration and contact-independent mechanisms involving
soluble TGF-β and IL-10 have been invoked to describe
the function of these Tregs [11]. These cells originate
from thymus in response to self-antigens [9]. Their roles
in allergen-specific immune reactions include suppres-
sion of dendritic cells that support the generation of ef-
fector T cells; inhibition of functions and migration of
effector Th1, Th2, and Th17 cells; elimination of pro-
duction of allergen-specific IgE and induction of IgG4
secretion; suppression of mast cells, basophils, and eo-
sinophils; interaction with resident tissue cells and par-
ticipation of tissue remodeling [12].Table 1 Characteristics of subsets of regulatory T cell (Treg)
Subset Specific marker Secretory
products
Actions







ICOS(+) Treg CD4, CD25, Foxp3, ICOS IL-10, IL-17,
IFN-γ
Suppress hapt
iTreg CD4, Foxp3 IL-10, TGF-β Similar to nTr
Tr1 CD4, CD25 IL-10 Suppress effec
functions [4]; s
and eosinoph
CD8(+)Treg CD8, Foxp3, CD25












IL-17 Inhibit the pr
T cells [10].
nTreg = natural regulatory T cell; ICOS = inducible costimulator; iTreg = inducible/ad
GB = granzyme B; RORGTF = RORgammat transcription factor.Very recently, CD4(+)CD25(+)CD127(lo/-) Foxp3(+)
Tregs are detected in the neonatal thymus. These cells
suppress the proliferative response to allogeneic stimula-
tion of CD4(+)CD25(−) T cells dose dependently. It is
also found that Treg turnover and suppressive function
increases with age and paralleled the increase in global
thymic Foxp3 mRNA expression in nonatopic children,
whereas Treg cell maturation is significantly delayed in
atopic children, implicating that the immune dysregula-
tion in atopic children might predispose to allergic disease
[13]. It has also been reported inverse correlation between
expression of FoxP3 and CD127 in CD4 + CD25+ T cells,
which suggests that cell surface expression of CD127 can
be used as a flexible alternative to the transcription factor
FoxP3 for identifying and isolating human Tregs for func-
tional analysis [14].
ICOS(+) Tregs are distinguishable from all other Foxp3
(+) Tregs by the expression of IL-10, IL-17, and interferon
(IFN)-gamma. ICOS(+) Tregs derived from the expansion
of nTregs rather than generation of adaptive Tregs in re-
sponse to their cognate antigen. CD25(+)Foxp3(+)ICOS(+)
phenotype expresses high levels of ICOS in vivo following
sensitization with 2,4-dinitro-fluorobenzene, and specific-
ally suppresses hapten-reactive CD8(+) T cells with super-
ior suppressive activity [15].
iTregs
In contrast to nTregs, iTregs are peripherally induced
Tregs. Naive CD4+ T cells in the periphery are induced to
express Foxp3 in response to foreign antigens [9] and these
cells have suppressive function similar to nTregs [16].Location
oliferation, suppression of DCs,
ffector Th1, Th2, and Th17 cells;
uction of allergen-specific IgE,
ecretion; suppress mast cells,
eosinophils; interact with
cells and participate tissue
2]
Thymus [9]
en-reactive CD8(+) T cells [15] Generated from nTregs
eg [16] Periphery
tor Th cell migration and
uppress mast cells, basophils,
ils [8]
Generated from non-Treg cell precursors
and home lungs and draining lymph
nodes [18]
n of naive or effector T cells;
IgE antibody responses [9], IL-4
d the proliferation of CD4(+)
Generated from OT-1 CD8 cells [9]and
tonsils
oliferation of CD4(+) effector Differentiated from CD4(+)Foxp3(+)CCR6(−)
Tregs in peripheral blood and lymphoid
tissue [10]
aptive regulatory T cell; Tr1 cell = IL-10-producing type 1 regulatory T cell;
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if generated early enough in life [4]. In addition, Th3 cells
that secrete TGF-β and IL-10 belong to this subset [17].
Tr1 cells
The CD4+ T cells that do not express Foxp3, but secret
IL-10 and suppress effector functions of Th cells are
known as Tr1 cells [4]. It was reported that intravenous
immunoglobulin injection in OVA-sensitized and OVA-
challenged mice induced production of Tr1 cells from
non-Treg cell precursors. These induced Tr1 cells home
specifically to the lungs and draining lymph nodes [18].
Their roles in allergen-specific immune reactions in-
clude inhibition of functions and migration of effector
Th2 cells; and suppression of mast cells, basophils, and
eosinophils [8].
CD8 + Tregs
A subset of Tregs expressing CD8 is rapidly gener-
ated from OT-1 CD8 cells in the presence of IL-4 and
IL-12, produce IL-10, and exhibits a unique cell-surface
phenotype with coexpression of activation and naive cell-
associated markers [9]. They are also observed in tonsils,
but rarely detected in peripheral blood. These Foxp3(+)
CD8(+) T cells can be induced in vitro in naive CD8(+)
T cells by polyclonal stimulation, which express predomin-
antly CD25(high) and CD28(high), and produce high levels
of TNF-α, IFN-γ, and granzyme B. Similarly, tonsillar
Foxp3(+)CD8(+) T cells also generate TNF-α and IFN-γ.
However, tonsillar Foxp3(+)CD8(+) T cells do not express
IL-17A, mostly CD25 negative, and express low CD127
and CD69. These Foxp3(+)CD8(+) T cells block activation
of naive or effector T cells by direct T-cell-T-cell inter-
action that antagonizes T-cell-receptor (TCR) signals, and
suppress IgG/IgE antibody responses [9], IL-4 expression
and the proliferation of CD4(+) T cells [19].
IL-17-producing Foxp3+ Tregs
It is reported that human peripheral blood and lymphoid
tissue, but not thymus contain a significant number of
CD4(+)Foxp3(+) T cells that express CCR6 and have the
capacity to produce IL-17 upon activation. These cells
coexpress Foxp3 and RORgammat transcription factors.
The CCR6(+)IL-17-producing Foxp3+ Tregs strongly in-
hibit the proliferation of CD4(+) responder T cells. Human
CCR6(+) IL-17-producing Foxp3+ Tregs are differentiated
from CD4(+)Foxp3(+)CCR6(−) Tregs upon T-cell recep-
tor stimulation in the presence of IL-1beta, IL-2, IL-21,
IL-23, and human serum [10]. However, a recent report
demonstrates that IL-17-producing Foxp3+ Tregs are a
novel crossover immune cell population, which could be
converted from Tregs to Th17 cells, and associated with a
decreased suppressive function of Foxp3 CD4(+) T lym-
phocytes [20].Cell signaling of Tregs and potential mechanisms of
their actions
Cell signaling of Tregs
As many as 5 subsets of Tregs make Tregs as one of
the most complicated T cell groups. Surely, more novel
subsets of Tregs will be discovered and their biological
functions will be investigated. It is very difficult to
understand the reasons why so many subsets of Tregs
are needed, and how these cells are generated without
looking into the intracellular signaling pathways of
these cells, and their migration routes. While the cellu-
lar signaling pathways and migration of Tregs remain
largely uninvestigated the Figure 1 summarizes the mo-
lecular mechanisms involved in cell signaling pathways.
Apart from Foxp3 mediated signaling pathways, it was
reported that signal transducer and activator of tran-
scription 4 (STAT4) is critical for IL-12 inhibited the
development of TGF-β1-induced-expressing iTregs, al-
though there is a parallel pathway involving T-bet [21].
It is found that IL-4 supersedes Treg function via the
IL-4Ralpha-STAT6 axis, which decreases Foxp3 expression
in Tregs and promotes the development of allergic inflam-
mation [22]. Moreover, infectious tolerance mediated by
membrane-bound TGF-β expressed on Tregs can be com-
promised by the competing effects of IL-4-induced signal-
ing in naive CD4(+) Th cells [23]. Development of CD8
Tregs is directly induced via STAT4 and STAT6 signaling
pathways irrespective of TCR signals [9].
Potential mechanisms of their actions
Migration to the involved inflammatory area is one of
the properties of inflammatory cells including Tregs. It
has been found that Foxp3+ Tregs share major non-
lymphoid tissue trafficking receptors, such as CCR4,
CCR5, CCR6, CXCR3, and CXCR6 with Th17 cells, im-
plicating that these T cells migrate to and within lymph-
oid tissues [24]. It has been previously summarized that
the mechanisms used by Treg cells to suppress a large
number of distinct target cell types can be broadly di-
vided into those that target T cells (suppressor cytokines,
IL-2 consumption, granzyme-perforin-induced apoptosis
of effector lymphocytes) and those that primarily target
antigen-presenting cells (decreased costimulation or de-
creased antigen presentation) [25]. However, anyone or
more mechanisms can be used by Tregs in a defined type
of inflammation.
Actions of Tregs on other immune cells
The suppressive actions of Tregs on other immune cells
such as effector T cells, B cells, eosinophils and mast
cells may help to explain the reasons why Tregs are cap-
able of controlling acquired immunity. In order to demon-
strate the issue more clearly we summarize the actions of
Tregs on other cell types in Figure 2.
Figure 1 Cell signaling pathways of Tregs. TGF-β = transforming growth factor beta; TGF-βR = transforming growth factor beta receptor;
RA = retinoic acid; RAR = retinoic acid receptor; TCR = T cell receptor; IL = interleukin; ILR = interleukin receptor; Smad = small body size and
mothers against decapentaplegic; ERK = extracellular regulated protein kinase; Jnk = Jun N-terminal kinase; PLCγ = phospholipase C gamma;
PKC = protein kinase C; TAK = TGF beta activated kinase; NFkB = nuclear factor kappa B; PI3K = phosphoinositide 3 kinase; AKT = protein kinase
B; JAK = Janus-family tyrosine kinase; STAT = signal transducer and activator of transcription; T bet = T cell specific T-box transcription factor;
Bcl-2 = B cell leukemia 2 protein; Foxp3 = forkhead box P3; CNS = non-coding sequence.
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Mast cells are essential for immediate allergic reactions,
and degranulation of this cell type is a hallmark of
allergy [26]. As the classic primary effector cells, mast
cells are responsible largely (if not all) for initiation of al-
lergic pathological damage and clinical symptoms. Re-
cently, it has been shown that constitutive Foxp3(+)
Treg can control the symptomatic phase of mast cell ac-
tivation and IgE-dependent anaphylaxis in mice [27], but
enhance IL-6 release from mast cells. Inhibition of mast
cell degranulation by Tregs appears via OX40/OX40 lig-
and interactions whereas inhibition of IL-6 release seems
via TGF-β [28]. In vitro studies demonstrate that IL-4
and TGF-β1 had balancing effects on mast cell survival,
migration, and FcepsilonRI expression, with each cyto-
kine cancelling the effects of the other. Dysregulation of
this balance may impact allergic disease and be amen-
able to targeted therapy [29].Tregs and Th cells
On activation, T cells undergo distinct developmental
pathways, attaining specialized properties and effector
functions. Th cells are traditionally thought to differenti-
ate into IFN-gamma-secreting Th1, IL-4/IL-5-secreting
Th2, and IL-17-secreting Th17 cells. Th1 cells are neces-
sary to clear intracellular pathogens, Th2 cells are im-
portant for clearing extracellular antigens, and Th17
cells have been shown to have a crucial role in the in-
duction of autoimmune tissue injury.
It has been reported that TGF-beta1 produced by
Foxp3-expressing Tregs is required to inhibit Th1-cell
differentiation and promote Th17-cell differentiation [30].
On the other hand, it appears that nitric oxide-induced
Tregs inhibit Th17 but not Th1 cell differentiation and
function [31]. Tregs can also inhibit IFN-γ synthesis with-
out blocking Th1 cell differentiation [32]. These discrimi-
nations could be due to different experimental system
Figure 2 Influence of Tregs on other cell types. Th = helper T cells; iTreg = inducible/adaptive regulatory T cell.
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that Tregs can inhibit the development of allergy via sup-
pression of other effector Th1, Th2, Th17 cells [33]. While
specific nTregs were highly effective at inhibiting the
polarization of naïve CD4(+) T cells into a Th2 phenotype
[34], Foxp3(+) Tregs promote Th17 cell development
in vivo through regulation of IL-2 [35]. It is found that IL-6
and TGF-beta together induce the differentiation of patho-
genic Th17 cells from naive T cells [36].
Tregs and DCs
DC is the major antigen presenting cells, which play a
pivotal role in the sensitization phase of allergic inflam-
mation. It is one of the major targets of Treg-mediated
suppression. Some studies have suggested that Treg-
mediated suppression of DC function is mediated by the
interaction of CTLA-4 on Tregs with CD80/CD86 on
the DCs resulting in downregulation of CD80/CD86 ex-
pression and a decrease in costimulation. A recent study
demonstrates further that the major suppressive mech-
anism of DC function by iTregs is secondary to the ef-
fects of IL-10 on MARCH1, an E3 ubiquitin ligase andCD83 expression [37]. Development of tolerogenic DC
phenotype may be of importance for prevention of al-
lergic contact dermatitis. Activated IL-10(+) Treg cells
might induce production of the tolerogenic CD11c(+)
DCs, and leads to the generation of hapten-specific
CD8(+) Treg cells, which protect against contact hyper-
sensitivity [38].
Tregs and eosinophils
Eosinophils is one of the secondary effector cells of
allergy. It is reported that Tregs are able to inhibit
the activity of eosinophils [39], and a negative correl-
ation between the number of eosinophils and the per-
centage of Foxp3(+) cells is found in BAL from tolerant
mice [40].
Tregs and Bregs
In recent years, regulatory B cell (Breg)s, a subset of B
cells which express Foxp3 and secretion of inhibitory
cytokine IL-10 and/or TGF-β have been discovered [41].
IL-10-producing B cells were the first regulatory B cells
to be recognized and were termed ‘B10’ cells, which is
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a TGF-β-producing Breg subset Br3 has been shown to
be related to immune tolerance in food allergies. More-
over, Foxp3-expressing B cells have also been identified
in humans and may act as Bregs (B-Foxp3 cells). The
functional image of regulatory B cells is similar to that
of Tregs [42]. The Breg subtypes may be homologous to
the Treg subtypes (Br1 cells expressing IL-10, Br3 cells
expressing TGF-β), although the Br1 subtype seems to
predominate.
Bregs act earlier, facilitating the recruitment of Tregs
then disappearing once the Tregs become operational.
Therefore, Bregs may play an important role in auto-
immune and allergic diseases [43]. Bregs induced pul-
monary infiltration of Tregs seems independent of TGF-β.
Because of the proliferative and apoptotic responses of Br1
and Br3 cells in immune tolerance in non-IgE-mediated
food allergy, reciprocal roles and counter-regulatory mech-
anisms of Br1 and Br3 responses are suspected [42].
Chronic helminth infections are associated with the ex-
pression of regulatory networks such as Tregs and Bregs
necessary for downmodulating allergic immune re-
sponses to harmless antigens [44]. It is found that helminth
Schistosoma mansoni infection induced IL-10-producing
CD1d(high) Bregs that could prevent ovalbumin-induced
allergic airway inflammation following passive transfer to
ovalbumin-sensitized recipients. The transfer of Bregs can
reverse established airway inflammation in ovalbumin-
sensitized mice via Tregs [45].
Contribution of Tregs to allergy
There is increasing interest in the role of both nTreg
and iTreg populations in preventing hypersensitive im-
mune responses and the underlying sensitization to al-
lergens. As early as 2006, it was summerized that Tregs
may actively prevent Th2 responses to allergens occur-
ring in healthy non-atopic individuals and that their
functions may be impaired in allergic patients [46]. It
has been suggested that peripheral T-cell tolerance to
environmental antigens is crucial for avoidance of al-
lergy, and aberrant activation of Th2 cells in allergy is
secondary to impaired mechanisms of peripheral T-cell
tolerance that is normally mediated by antigen-specific
T-cell anergy, Tregs and suppressive cytokines, IL-10
and TGF-β. Therefore, a most appealing therapy for al-
lergic diseases would be an allergen-specific immuno-
therapy [47] that reduces Th2 cytokine production and
promotes induction of anergy, Treg and suppressor cyto-
kines [48]. Very recently, it is found that tonsil pDCs
have the ability to generate functional CD4(+)CD25(+)
CD127(−)Foxp3(+) Tregs with suppressive property from
naive T cells, and that functional allergen-specific Tregs
are identified both in lingual and in palatine tonsils. Since
lingual tonsil is anatomically big and remains lifelongintact, it may serve as potential first-line organs of oral
tolerance against allergens [49]. In order to further
understand the roles of Tregs in allergy, we summarized
the involvement of Tregs in different allergic diseases
(Table 2).
Tregs in allergic dermatitis
Very recently, in a murine atopic dermatitis model, the
numbers of nTregs are found increase in the allergen-
exposed skin area and in the secondary lymphoid or-
gans, and CD103+ effector/memory Tregs are observed
to expand gradually in the lymph nodes throughout the
sensitization protocol. The depletion of Tregs leads to sig-
nificantly exacerbated skin inflammation, including in-
creased recruitment of inflammatory cells and expression
of Th2 cytokines, as well as elevated serum IgE levels [50].
It is also found that the ratio of Foxp3+/CD4+ cells ap-
pears skewed towards effector T cells associated with in-
flammation in the margin and centre of the psoriatic
plaque, and that increased IL-17 is mostly related to mast
cells, and only sporadically to T cells [51].
Tregs in allergic rhinitis
A study which investigated allergen-induced Th2, Th1
and Treg immune responses in peripheral blood mono-
nuclear cells (PBMC) and their association with symptom
improvement in allergic rhinitis patients after 3 years of
SIT shows that both IL-4 expression and the IL-4/IFN-
gamma ratio are decreased in patients with a good thera-
peutic outcome after 1 year of SIT, whereas the induced
Treg and Th1 responses persists over 3 years of SIT [52].
Tregs in allergic lower airway inflammation
It was reported in 2007 that diverse populations of Tregs
play an important role in regulating Th2 responses to al-
lergens, maintaining functional tolerance. In experimen-
tal asthma models, Tregs can suppress Th2 responses
to allergen, airway eosinophilia, mucous hypersecretion,
and airway hyperresponsiveness (AHR) [53]. After a
long-term aerosol challenge, referred to as local inhala-
tional tolerance, ovalbumin induced allergic airway in-
flammation resolves with increased number of Tregs,
reduced number of T and B lymphocytes in bronchoal-
veolar lavage fluid and hilar lymph node [54]. Depletion
of Tregs during the sensitizing phase of an active im-
mune response led to a dramatic exacerbation of allergic
airway inflammation in mice, suggesting an essential role
of Tregs in regulating immune responses against aller-
gens as early as the sensitization phase via maintenance
of functional tolerance [55]. Furthermore, antigen-induced
airway hyperreactivity can be completely suppressed by
adoptive transfer of Tregs overexpressing active TGF-β1
and IL-10 [56]. Recent work has demonstrated that Foxp3
expression is reduced and CD25(hi) Treg-suppressive
Table 2 Involvement of regulatory T cell (Treg)s in different allergic diseases
Disease Location Involvement of Tregs
Allergic dermatitis Skin, the secondary lymphoid organs The depletion of Tregs leads to significantly exacerbated skin inflammation,
as well as elevated serum IgE levels [50].
Allergic rhinitis Tonsil, Blood Potential first-line organs of oral tolerance against allergens [49]; allergic
rhinitis patients with a good therapeutic outcome after 1 year of SIT, the
induced Treg and Th1 responses persist over 3 years of SIT [52].
Allergic airway inflammation Blood, peribronchial lymph nodes Foxp3 expression is reduced and CD25(hi) Treg-suppressive function is
deficient in asthma. Corticosteroids and allergen immunotherapy act on
Tregs, in part to increase IL-10 production, while vitamin D3 and long-acting
beta-agonists enhance Tr1 cell function [57]. Heligmosomoides polygyrus
infection is associated with elevated numbers of Tregs in airway challenged
mice [60], efficiently protects mice from asthma by induction of accumulation
of highly suppressive Tregs in the lungs [61].
SIT = specific immunotherapy.
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corticosteroids and allergen immunotherapy act on Tregs,
in part to increase IL-10 production, while vitamin D3 and
long-acting beta-agonists enhance Tr1 cell function [57].
In addition, Treg-specific ablation of the E3 ubiquitin ligase
Itch in mice causes massive multiorgan lymphocyte infil-
tration and development of severe antigen-induced pul-
monary inflammation, which unveils a mechanism of Treg
acquisition of Th2-like properties that is independent of
Foxp3 function and Treg cell stability [58]. All these find-
ings indicate the pivotal role of Tregs in allergic airway
inflammation. It is recognized that IL-2 is needed to main-
tain Foxp3+ Tregs in the periphery [4]. Therefore, a cyto-
kine:antibody complexes of IL-2 and anti-IL-2 mAb reduce
the severity of allergen-induced inflammation in the lung
by expanding Tregs in vivo. Following IL-2:anti-IL-2 treat-
ment, airway inflammation and eosinophilia is dampened,
and mucus production, AHR to methacholine and paren-
chymal tissue inflammation are also dramatically reduced.
The IL-2:anti-IL-2 treatment is dependent on Treg-derived
IL-10, and suggests that endogenous Treg therapy may be
a useful tool to combat asthma [59].
It has long been observed that some helminth infec-
tions are negatively associated with the prevalence of
allergic disorders. Using heligmosomoides polygyrus
(H. polygyrus) in a murine model of allergic airway disease
and of atopic dermatitis, it is found that mice concomi-
tantly infected with H. polygyrus diminishes eosinophil
and lymphocyte recruitment into the lungs and decreased
allergen-specific IgE levels. The worm infection is associ-
ated with significantly elevated numbers of Tregs in peri-
bronchial lymph nodes in airway challenged mice. On the
other hand, mast cell recruitment is significantly in-
creased, and Tregs are basically absent in eczematous skin
and remained the same in skin-draining lymph nodes in
worm-infected allergic dermatitis mice, suggesting that in-
fection with the gastrointestinal nematode leads to signifi-
cant inhibition of mucosa-associated but not cutaneous
allergic reactions [60]. Moreover, it has been reportedrecently that a bacterial pathogen Helicobacter pylori
(H. pylori) infection efficiently protects mice from asthma
by induction of impaired maturation of lung-infiltrating
DCs and the accumulation of highly suppressive Tregs in
the lungs. Since systemic Treg depletion abolishes asthma
protection it suggests that the action of H. pylori is via
Tregs [61]. The B subunit of E. coli heat-labile enterotoxin
(EtxB) treatment diminishes eosinophilia in bronchoalveo-
lar lavage, reduces OVA-specific IgE and IL-4 production
locally and systemically, and reduces AHR in a mouse
model of asthma. EtxB induces a dose-dependent increase
in OVA-specific CD4(+)Foxp3(+) T cells in the lung and
systemically, suggesting that the action of. EtxB on the
mice is through iTregs [62].
Roles of Tregs in treatment of allergy
It has been recognized that Tregs are involved in the
treatment of allergic diseases, which helps to explain
some therapeutic mechanisms that puzzle us for decades.
The potential roles of Tregs in anti-allergic therapies are
summarized in Table 3.
In specific immunotherapy
Antigen specific respiratory tolerance is mediated by
lung DCs producing IL-10, which induce the develop-
ment of Tregs. The development of respiratory tolerance
also depends on co-stimulation (CD86, and the ICOS-
ICOSL pathway). Although exposure of the respiratory
mucosa to some pathogenic agents (especially virus, and
endotoxin) is associated with asthma exacerbations, mi-
crobial exposure may also promote mucosal tolerance
and protection against the development of allergic dis-
eases. Mucosal-based immunotherapy has been already
used as an alternative form of allergen delivery in im-
munotherapy [63]. Allergen-specific immunotherapy is
the only treatment that leads to reverse established aller-
gic disease and lifelong tolerance to previously disease-
causing allergens by restoring normal immunity against
allergens. Tregs are involved in preventing sensitization
Table 3 Therapeutic actions of regulatory T cell (Treg)s in allergic diseases
Therapy Action of Tregs
SIT Suppression of T cell responses to the T-cell epitopes of major allergens. Autocrine action of IL-10 and/or TGF-β,
which are produced by antigen-specific Tregs. They may suppress IgE production and induce IgG4 and IgA
production against allergens [65]. Histamine released from mast cells and basophils may efficiently contribute to
immunoregulation, and affect Tregs [6]. Der p immunotherapy causes increased number of Treg cells, and
elevated IL-10 production. IL-10(+) Tregs may respond to Der p-2 and down-regulate NF-κB/p65 expression in
PBMC to maintain immune tolerance during SIT [66].
SLIT Allergen extracts administered via the sublingual route are long retained at mucosal level, where the allergen
molecules are captured by DCs, following their migration in the draining lymph nodes, presented to T cells to
generate iTregs [64]. SLIT causes the absence of effectors cells, such as mast cells, basophils and eosinophils in
the oral mucosa of allergic subjects. Skewing of allergic-specific effector T cells to a Tr1 phenotype appears to be a
critical event in successful allergen-specific immunotherapy and glucocorticoids and beta2-agonists treatment [8].
Bacteria therapy Lactobacilli prime of DCs to drive the development of Tregs. These Tregs produce increased IL-10 inhibiting the
proliferation of bystander T cells [4].
Treg therapy Transfer of OVA peptide-specific CD4 + CD25+ Tregs to OVA-sensitized mice reduces AHR, recruitment of
eosinophils, and Th2 cytokine expression in the lung after allergen challenge [70].
SIT = specific immunotherapy; Der p = Dermatophagoides pteronyssinus; PBMC = peripheral blood mononuclear cells; SLIT = sublingual immunotherapy; AHR = airway
hyperresponsiveness; OVA = ovalbumin.
Zhang et al. Journal of Translational Medicine 2014, 12:125 Page 8 of 11
http://www.translational-medicine.com/content/12/1/125to allergens by suppression of T cell responses to the
T-cell epitopes of major allergens. It is initiated by
the autocrine action of IL-10 and/or TGF-β, which are
produced by antigen-specific Tregs. They may suppress
IgE production and induce IgG4 and IgA production
against allergens. In addition, histamine released from
mast cells and basophils may efficiently contribute to im-
munoregulation during specific immunotherapy, and
affect Treg cells and the production of their cytokines via
histamine receptor 2 [6].
Sublingual immunotherapy (SLIT) is an effective and
safe treatment for respiratory allergy. Studies of pharma-
cokinetics shows that allergen extracts administered via
the sublingual route are not directly absorbed by the oral
mucosa but are long retained at mucosal level, where
the allergen molecules are captured by DCs, following
their migration in the draining lymph nodes, presented
to T cells to generate iTregs. This is at least for the
long-term effects, and for the short-term efficacy, ob-
served with ultrarush or coseasonal treatment, a down-
regulation of mast cells resulting in hyporeactivity at the
peak of the pollen season may be suggested [64]. Indeed,
SLIT causes the absence of effectors cells, such as mast
cells, basophils and eosinophils in the oral mucosa of
allergic subjects. Skewing of allergic-specific effector
T cells to a Tr1 phenotype appears to be a critical event
in successful allergen-specific immunotherapy and glu-
cocorticoids and beta2-agonists treatment. Tr1 suppresses
Th2 cells and effector cells of allergic inflammation, such
as eosinophils, mast cells, basophils, through producing
IL-10 [8], and TGF-β [65]. The increased levels of IL-10
and TGF-β that are produced by Tregs potently sup-
press IgE production, while simultaneously increasing
production of non-inflammatory isotypes IgG4 and IgA,
respectively [65]. NF-κB acts as a mater switch for
allergic inflammation. Dermatophagoides pteronyssinus(Der p) immunotherapy causes increased numbers of
Foxp3+ CD4+ Tregs, and elevated IL-10 production
with decreased IRAK-1 and NF-κB/p65 nuclear trans-
location. IL-10(+) Tregs may respond to Der p-2 and
down-regulate NF-κB/p65 expression in peripheral blood
mononuclear cells to maintain immune tolerance during
immunotherapy [66].
In other therapies
Parasite infection does not prevent allergen sensitisation,
but restricts the Th2 effector phase responsible for in-
flammation. Suppression of allergic inflammation can be
transferred by Tregs from an infected, allergen-naïve
animal to an uninfected, sensitized recipient [67]. This
may due to at least in part that infections increase the
activity of Tregs, which suppress effector mechanisms of
both Th1 and Th2 types [68].
Using green fluorescent protein (GFP)-Foxp3 knock-in
reporter mice, it is found that intravenous immuno-
globulin (IVIG) markedly improves OVA-induced airway
hyperresponsiveness characterized by 4- to 6-fold en-
hancement in Tregs in pulmonary and associated lymph-
oid tissues. Induction of Tregs is mediated by tolerogenic
DCs generated after IVIG exposure. IVIG-primed DCs
express altered Notch ligands, including increased Delta-
4 and reduced Jagged-1 levels, reflecting decreased Th2
polarization. Furthermore, IVIG-primed DCs can stimu-
late Treg differentiation from uncommitted Foxp3(−)
CD4(+) T cells ex vivo [18]. It is now well recognized that
microorganisms can induce the generation of suppressive
cytokines TGF-beta and IL-10 [4]. Two different species
of lactobacilli, Lactobacillus reuteri and Lactobacillus
casei are able to prime of monocyte-derived immu-
nomodulation DCs to drive the development of Tregs
by binding the C-type lectin DC-specific intercellular
adhesion molecule 3-grabbing non-integrin (DC-SIGN).
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capable of inhibiting the proliferation of bystander T cells
in an IL-10-dependent fashion. The probiotic bacteria
might be used in the treatment of a number of inflamma-
tory diseases, including atopic dermatitis and Crohn’s
disease [69].
Transfer of OVA peptide-specific CD4 + CD25+ Tregs
to OVA-sensitized mice reduces AHR, recruitment of
eosinophils, and Th2 cytokine expression in the lung
after allergen challenge. This suppression is dependent
on IL-10 because increased lung expression of IL-10 is
detected after transfer of Tregs, and regulation is re-
versed by anti-IL-10 receptor antibody. Tregs can sup-
press the Th2 cell-driven response to allergen in vivo by
an IL-10-dependent mechanism but that IL-10 produc-
tion by the Tregs themselves is not required for such
suppression [70].
Tregs in early life
The concept of iTregs has considerable significance in
preventing asthma if generated early enough in life. This
is because cytokines such as IL-4 and IL-6 inhibit Foxp3
induction in naive CD4+ T cells and therefore de novo
generation of Tregs can be expected to be less efficient
when it is concomitant with effector cell development in
response to an allergen. However, if iTregs can be in-
duced, the process of infectious tolerance would facili-
tate expansion of the iTreg pool. There may be an
opportunity in early life in the context of a relatively im-
mature immune system that is permissive for the gener-
ation of iTregs specific to a spectrum of allergens that
would regulate asthma for lifelong [4]. A recent study
shows that the timothy- and birch-allergic mothers re-
spond with increased proliferation and/or IL-4 produc-
tion towards timothy and birch extract. However, cord
blood mononuclear cell proliferation, phenotype of T
cells, Foxp3(+) Tregs and B cells in response to the aller-
gens are not affected by the allergic status of the mother
[71]. Fetal exposures have been investigated as risk fac-
tors of early life allergic disease, and it is showed that
nTreg levels during pregnancy in venous blood samples
vary in association with both dog and cat exposure and
atopic status [72].
Summary
Tregs have been emerging as key focus in the sensitization
phase of the pathogenesis of allergy. Through acting upon
other cell types, Tregs seem to control acquired immun-
ity in the body. Based upon the information available,
we propose that Tregs should be classified into 5 sub-
groups: nTregs including ICOS)(+) Tregs, iTregs, Tr1
cells, CD8(+) Tregs, and IL-17-producing Tregs. These
cells share some common features including expression
of Foxp3, and secretion of inhibitory cytokine IL-10 and/orTGF-β. However, signaling pathways of Tregs remain
largely uninvestigated.
In recent years, there is increasing interest in the role
of both nTreg and iTreg populations in preventing
hypersensitive immune responses and the underlying
sensitization to allergens. Since eliminated actions of
Tregs may increase the chance for sensitive individuals
to suffer from allergy, we summarized the involvement
of Tregs in different allergic diseases. It has been sug-
gested that peripheral T-cell tolerance to environmental
antigens is crucial for avoidance of allergy. Therefore a
most appealing therapy for allergic diseases would be
SIT that reduces Th2 cytokine production and promotes
induction of T cell anergy, Tregs and suppressor cyto-
kines. Tregs are also involved in other immune therapies
such as parasite or bacterial infections to treat allergy.
In conclusion, at least 5 subsets of Tregs are derived
from naive T cells under different conditions, but exact
role of each subtype of them in controlling allergic dis-
eases remains obscure. It is widely accepted that Tregs
play a pivotal role in the development of allergy, par-
ticularly in the sensitization phase. Therefore targeting
Tregs can be a useful therapy for prevention and treatment
of allergy.
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